PAVE Home

PAVE 100

One important initiative currently being undertaken by PAVE is a collaborative clinical trial currently referred to as PAVE 100, or the Pave Study. The study will be a phase IIb clinical trial to evaluate the efficacy, safety and immunogenicity of a multiclade HIV-1 DNA Plasmid Vaccine. more >>

PAVE is a voluntary consortium of U.S. government agencies and key U.S. government-funded organizations involved in the development and evaluation of HIV/AIDS preventive vaccines and the conduct of HIV vaccine clinical trials.

The goal to develop a safe and effective HIV vaccine is one that no single entity or institution is likely to accomplish on its own. Therefore, PAVE's goal is to achieve better harmony and increased operational and cost efficiencies in HIV vaccine development and in the conduct of HIV vaccine clinical trials, especially phase III trials, through serving as a forum and clearinghouse for information sharing and planning. PAVE will also serve to eliminate unnecessary duplication of effort. PAVE is a synergistic partnership that pools intellectual resources and experience to achieve fundamental goals that a number of U.S. government agencies and others share in common. PAVE does not represent a funding organization, and members are expected to support their activities from other governmental or non-governmental sources.


About PAVE Mission/Goals Areas of Collaboration Membership Working Groups FAQs Additional Links Contact Executive Steering Group ESG Overview ESG Role ESG Roster Affiliate Membership Affiliate Roster Benefits/Responsibilities How to Apply	PAVE 100 One important initiative currently being undertaken by PAVE is a collaborative clinical trial currently referred to as PAVE 100, or the Pave Study. The study will be a phase IIb clinical trial to evaluate the efficacy, safety and immunogenicity of a multiclade HIV-1 DNA Plasmid Vaccine. more >> PAVE is a voluntary consortium of U.S. government agencies and key U.S. government-funded organizations involved in the development and evaluation of HIV/AIDS preventive vaccines and the conduct of HIV vaccine clinical trials. The goal to develop a safe and effective HIV vaccine is one that no single entity or institution is likely to accomplish on its own. Therefore, PAVE's goal is to achieve better harmony and increased operational and cost efficiencies in HIV vaccine development and in the conduct of HIV vaccine clinical trials, especially phase III trials, through serving as a forum and clearinghouse for information sharing and planning. PAVE will also serve to eliminate unnecessary duplication of effort. PAVE is a synergistic partnership that pools intellectual resources and experience to achieve fundamental goals that a number of U.S. government agencies and others share in common. PAVE does not represent a funding organization, and members are expected to support their activities from other governmental or non-governmental sources. Printable View